Core Insights - Kuros Biosciences has launched the MagnetOs™ MIS Delivery System, designed for minimally invasive surgical procedures, which will be showcased at the SMISS Annual Meeting on October 3, 2025 [1][4]. Product Features - The MagnetOs MIS Delivery System is the only sterile, prefilled, and human tissue-free bone graft delivery system, supported by Level I clinical evidence [2]. - It utilizes proprietary NeedleGrip™ submicron surface technology to enhance bone formation by harnessing the immune system, ensuring efficient and precise graft placement [2][8]. - The system allows for graft placement that is three times faster than traditional methods, and it is ready-to-use without the need for refrigeration or thawing [7]. Clinical Evidence - A retrospective study showed a 94.4% fusion rate in patients undergoing minimally invasive and open transforaminal lumbar interbody fusions (TLIF) using MagnetOs, even among patients with comorbidities [6]. - MagnetOs demonstrated nearly double the fusion rate of autograft in posterolateral fusion procedures (79% vs. 47%) in a Level I clinical study [8]. Expert Endorsements - Dr. Matthew Maserati, a neurosurgeon, praised the MagnetOs MIS Delivery System for its efficiency and reliability in graft placement during his presentation at SMISS [3]. Company Vision - Chris Fair, CEO of Kuros Biosciences, emphasized that the launch of MagnetOs MIS reflects the company's commitment to redefining spine surgery through innovation, efficiency, and clinical evidence [4].